Patents Assigned to PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY
-
Publication number: 20230310554Abstract: The present invention is intended to provide a medicament for cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning, wherein the medicament does not cause side effects, is excellent in immediate effectiveness, and has a high antidotal effect. Specifically, the present invention relates to a medicament for cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning, wherein the medicament comprises, as an active ingredient(s), one or more selected from the group consisting of a heme protein capable of binding to cyanide ions (CN?), hydrogen sulfide ions (HS?) and azide ions (N3?), a substance containing a heme protein capable of binding to CN?, HS? and N3?, and a heme derivative capable of binding to CN?, HS? and N3?. More specifically, the present invention relates to a medicament or a pharmaceutical composition for the treatment or prophylaxis of cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning.Type: ApplicationFiled: August 27, 2021Publication date: October 5, 2023Applicants: KEIO UNIVERSITY, PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY, KIMIGAFUCHI GAKUENInventors: Kazuaki TAGUCHI, Yuto SUZUKI, Kazuaki MATSUMOTO, Hiromi SAKAI, Masaki OTAGIRI
-
Publication number: 20230220387Abstract: The present invention provides a D-serine transport modifier which is characterized by controlling the transport of D-serine into and out of cells by a D-serine transporter protein, a pharmaceutical composition which comprises the same as an active component and treats or prevents diseases relating to an increase or decrease in the amount of D-serine, and a screening method of substances that control the transport of D-serine. The present invention also provides a screening method of a D-serine transporter protein.Type: ApplicationFiled: December 25, 2020Publication date: July 13, 2023Applicants: Kagami Inc., Public University Corporation Nara Medical University, National Institutes of Biomedical Innovation, Health and NutritionInventors: Masashi MITA, Rikako SUZUKI, Shushi NAGAMORI, Pattama WIRIYASERMKUL, Pornparn KONGPRACHA, Satomi MORIYAMA, Tomonori KIMURA
-
Publication number: 20230156892Abstract: An illumination device includes a light emitter configured to emit illumination light and a controller configured to control the light emitter. The controller controls the illumination light such that a first decrease ratio of melanopic illuminance of illumination light during night-time illumination to melanopic illuminance of illumination light during daytime illumination is higher than a second decrease ratio of illuminance of the illumination light during the night-time illumination to illuminance of the illumination light during the daytime illumination.Type: ApplicationFiled: February 19, 2021Publication date: May 18, 2023Applicants: KYOCERA Corporation, Public University Corporation Nara Medical UniversityInventors: Katsuhiro MITSUI, Hidetaka KATOU, Kenji OBAYASHI
-
Publication number: 20220373565Abstract: An APTT prolongation factor estimation system includes one or more facilities each including an analyzer which measures a blood coagulation reaction of a subject blood specimen, a database which stores data on a blood coagulation reaction and APTT prolongation factor of blood specimens, and a computer which estimates an APTT prolongation factor of the subject blood specimen based on the data on the blood coagulation reaction from the analyzer and the data stored in the database. The facilities each further includes a data transmission unit which transmits, to the computer, the data on the blood coagulation reaction of the subject blood specimen obtained by the analyzer, and a data reception unit which receives a result of the estimation of the APTT prolongation factor, which is obtained by the computer, regarding the subject blood specimen measured by each of the analyzers.Type: ApplicationFiled: June 19, 2020Publication date: November 24, 2022Applicants: SEKISUI MEDICAL CO., LTD., PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITYInventors: Toshiki KAWABE, Yukio ODA, Midori SHIMA, Keiji NOGAMI, Kenichi OGIWARA, Naruto SHIMONISHI
-
Publication number: 20220326262Abstract: Provided is a method by which a titer of a coagulation factor inhibitor can be measured simply and in a short time. The present invention relates to a method for measuring a titer of a coagulation factor inhibitor. The method includes: preparing a mixed specimen containing a subject blood specimen and a normal blood specimen; heating the mixed specimen and acquiring a coagulation reaction curve for the heated mixed specimen; acquiring a coagulation reaction curve for the mixed specimen that has not been heated; calculating a parameter related to the coagulation reaction curve of the mixed specimen that has not been heated as a first parameter; calculating a parameter related to the coagulation reaction curve of the heated mixed specimen as a second parameter; and calculating a titer of a coagulation factor inhibitor in the subject blood specimen on the basis of the ratio or the difference between the first parameter and the second parameter.Type: ApplicationFiled: April 23, 2020Publication date: October 13, 2022Applicants: SEKISUI MEDICAL CO., LTD., PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITYInventors: Toshiki KAWABE, Yukio ODA, Mari EMMI, Midori SHIMA, Keiji NOGAMI, Kenichi OGIWARA, Naruto SHIMONISHI
-
Publication number: 20220146537Abstract: To provide a method for analyzing coagulation characteristics of a blood specimen. To provide a method for analyzing a blood specimen, including: acquiring a waveform related to a coagulation rate or coagulation acceleration of a sample obtained by mixing a subject blood specimen with a reagent for measuring coagulation time; extracting multiple parameters characterizing the waveform related to a coagulation rate or a coagulation acceleration; and determining an activity level or activity abnormality of a coagulation factor in the subject blood specimen on the basis of the multiple parameters.Type: ApplicationFiled: January 31, 2020Publication date: May 12, 2022Applicants: SEKISUI MEDICAL CO., LTD., PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITYInventors: Toshiki KAWABE, Yukio ODA, Midori SHIMA, Keiji NOGAMI, Kenichi OGIWARA
-
Patent number: 11150253Abstract: Disclosed is a method for analyzing a blood specimen, including the steps of: coagulating a blood specimen in the presence of an activating agent for fibrinolytic system to acquire a coagulation waveform; and acquiring information about fibrinolytic capacity of the blood specimen based on the acquired coagulation waveform.Type: GrantFiled: April 27, 2017Date of Patent: October 19, 2021Assignees: SYSMEX CORPORATION, PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITYInventors: Midori Shima, Keiji Nogami, Tomoko Matsumoto, Sho Shinohara, Nobuo Arai
-
Publication number: 20210282800Abstract: To provide a transplant-use tendon harvesting device that can harvest a tendon more easily. The transplant-use tendon harvesting device 1 includes a mantle portion 5 and a tendon separation element 8. The mantle portion 5 is configured to be inserted into a body from an incision portion 4 and moved along a tendon 3 to be harvested. The tendon separation element 8 is formed of an elastic member and attached to the mantle portion 5 to move along the tendon 3 together with the mantle portion 5 so as to separate an end portion of the tendon 3 on the moving direction side from another tissue. The tendon separation element 8 includes a separation functional portion 6 to cause the tendon 3 to pass inside at a time of moving along the tendon 3 to separate the tendon 3 and linear portions 11 and 12 inserted into the mantle portion 5 to be fixed.Type: ApplicationFiled: July 27, 2018Publication date: September 16, 2021Applicants: Public University Corporation NARA MEDICAL UNIVERSITY, Nara Seiko INC.Inventors: Yasuaki NAKANISHI, Shohei OMOKAWA, Hiroo NAKAGAWA
-
Patent number: 11078518Abstract: Various methods for evaluating hemostatic effect and various blood coagulation initiation reagents were studied to construct a method for evaluating blood coagulation reaction mediated by a substance having an activity of substituting for coagulation factor VIII (FVIII). As a result, it was discovered that by using a coagulation initiation reagent containing activated coagulation factor XI (FXIa) and phospholipids, the effect of a substance having an activity of substituting for coagulation factor VIII (FVIII) on blood coagulation reaction can be evaluated using the amount of thrombin generated in the blood sample as an indicator.Type: GrantFiled: September 26, 2013Date of Patent: August 3, 2021Assignees: Chugai Seiyaku Kabushiki Kaisha, Public University Corporation Nara Medical UniversityInventors: Tetsuhiro Soeda, Takehisa Kitazawa, Midori Shima
-
Publication number: 20210223270Abstract: A method for diagnosing interstitial cystitis includes measuring at least any one kind of lysophosphatidylcholine. A system and program for diagnosing a possibility of interstitial cystitis or bladder pain syndrome is also provided.Type: ApplicationFiled: November 5, 2019Publication date: July 22, 2021Applicants: Public University Corporation Nara Medical University, For You Medical Corporation, TOMO CO., LTD.Inventors: Kazumasa TORIMOTO, Kiyohide FUJIMOTO, Tomohiro UEDA
-
Publication number: 20210107994Abstract: The present inventors examined the procoagulant activity of a multispecific antigen-binding molecule that functionally substitutes for FVIII using blood and plasma derived from FIX disorder patients. The result showed that multispecific antigen-binding molecules that functionally substitute for FVIII can be used not only as methods for preventing and/or treating bleeding in hemophilia A, acquired hemophilia A, von Willebrand disease, and hemophilia C, which are caused by FVIII dysfunction, but also as methods for preventing and/or treating bleeding in FIX disorders, because of their procoagulant activity. Furthermore, the effect of a FIX formulation could be enhanced by using it in combination with a multispecific antigen-binding molecule that functionally substitutes for FVIII, and it was shown that the combined use is promising as a combination therapy that shows stable hemostatic effects.Type: ApplicationFiled: March 30, 2018Publication date: April 15, 2021Applicants: PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY, CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Midori Shima, Keiji Nogami, Kenichi Ogiwara
-
Publication number: 20200108099Abstract: The purpose of the present invention is to provide a novel treatment agent for pulmonary fibrosis for which there is currently no effective drug therapy established. The present invention is a therapeutic agent for pulmonary fibrosis containing mesenchymal stem cells. The pulmonary fibrosis is preferably usual interstitial pneumonia (UIP) or idiopathic pulmonary fibrosis (IPF). Also, the mesenchymal stem cells are preferably derived from adipose tissue or are allogeneic.Type: ApplicationFiled: February 9, 2018Publication date: April 9, 2020Applicants: ROHTO PHARMACEUTICAL CO., LTD., Public University Corporation Nara Medical UniversityInventors: Tetsuo Furuno, Toshihiro Ito, Hiroshi Kimura, Masanori Yoshikawa, Makiko Sawada
-
Publication number: 20190313921Abstract: A measurement device includes a pulse wave signal acquisition unit, a pulse wave velocity calculator, a transfer function calculator, a phase diagram classifier, and an aneurysm determinator. The pulse wave signal acquisition unit acquires time-series pulse wave signals of each of an upper arm and an ankle of the subject. The pulse wave velocity calculator obtains a brachial-ankle pulse wave velocity based on the pulse wave signal of the upper arm and the pulse wave signal of the ankle. The transfer function calculator calculates a transfer function from the pulse wave signal of the upper arm and the pulse wave signal of the ankle. The phase diagram classifier classifies the phase diagram of each subject into any one of four groups. The aneurysm determinator determines presence or absence of the abdominal aortic aneurysm by a criterion set according to each group.Type: ApplicationFiled: June 26, 2019Publication date: October 17, 2019Applicants: OMRON HEALTHCARE Co., Ltd., A SCHOOL CORPORATION KANSAI UNIVERSITY, PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITYInventors: Miki IMAMURA, Yukiya SAWANOI, Toshihiko OGURA, Hideo UTSUNO, Kimihiko KICHIKAWA, Shigeo ICHIHASHI, Shinichi IWAKOSHI
-
Patent number: 10383609Abstract: To provide a surgical instrument for performing incision that enables surgery to be performed safely and easily, with minimal invasiveness and a reduced risk of damaging a tissue, such as a tendon, nerve, or blood vessel. This surgical instrument enables a tendon sheath and an aponeurotic membrane to be incised safely without significantly incising the skin or subcutaneous tissue, and makes it possible to conduct surgery percutaneously at an extremely low level of invasion.Type: GrantFiled: December 24, 2014Date of Patent: August 20, 2019Assignees: PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY, NARA SEIKO INC.Inventors: Yasuaki Nakanishi, Akinobu Hakoda, Keiko Matsuyoshi
-
Patent number: 10302626Abstract: The present invention relates to a method for evaluating coagulability of a blood specimen obtained from a subject to whom a substance having a coagulation factor VIII-substituting activity is administered. The present invention also relates to a reagent for blood coagulation analysis, a reagent kit for blood coagulation analysis, and an apparatus for blood coagulation analysis. Furthermore, the present invention relates to an apparatus and computer program for evaluating coagulability of a blood specimen.Type: GrantFiled: October 24, 2017Date of Patent: May 28, 2019Assignees: PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY, CHUGAI SEIYAKU KABUSHIKI KAISHA, SYSMEX CORPORATIONInventors: Midori Shima, Keiji Nogami, Tomoko Matsumoto, Takehisa Kitazawa, Tetsuhiro Soeda, Yuka Ikeda
-
Patent number: 10215766Abstract: Disclosed is a blood sample determination method including: emitting light to a measurement specimen prepared by mixing a clotting time measuring reagent and a blood sample suspected to be derived from a subject having lupus anticoagulant or a coagulation factor inhibitor, to obtain optical information about an amount of light from the measurement specimen; obtaining at least one parameter regarding derivative of clot waveform, based on the obtained optical information; and determining, based on a value of the obtained parameter, whether the blood sample is suspected to be a sample derived from a subject having lupus anticoagulant or is suspected to be a sample derived from a subject having a coagulation factor inhibitor.Type: GrantFiled: December 15, 2015Date of Patent: February 26, 2019Assignees: PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY, SYSMEX CORPORATIONInventors: Midori Shima, Keiji Nogami, Yuka Tabuchi, Hiroshi Kurono
-
Publication number: 20180031539Abstract: Disclosed is a method for determining the severity of hemophilia, the method including the steps of: coagulating a blood specimen to acquire a coagulation waveform; acquiring an average change rate of a coagulation rate from the coagulation waveform; and determining the severity of hemophilia in the blood specimen based on the average change rate of the coagulation rate.Type: ApplicationFiled: July 27, 2017Publication date: February 1, 2018Applicants: SYSMEX CORPORATION, PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITYInventors: Midori SHIMA, Keiji NOGAMI, Tomoko MATSUMOTO, Yuka TABUCHI, Nobuo ARAI
-
Publication number: 20180011114Abstract: The inventors produced substances that neutralize the activity of a bispecific antibody having an activity of functionally substituting for FVIII, and undertook the construction of methods for measuring the reactivity of FVIII that can ensure accuracy even in the presence of this bispecific antibody. As a result, the inventors discovered that in APTT-based one-stage clotting assay, FVIII activity in the plasma of a hemophilia A patient can be evaluated accurately, and also that in APTT-based Bethesda assay, FVIII inhibitor titer in the plasma of a hemophilia A patient carrying a FVIII inhibitor can be evaluated accurately.Type: ApplicationFiled: September 24, 2015Publication date: January 11, 2018Applicants: PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY, CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Keiji Nogami, Midori Shima, Tetsuhiro Soeda, Takehisa Kitazawa
-
Patent number: 9857375Abstract: The present invention provides a novel cancer marker that is useful in the diagnosis of urothelial cancer. The present invention uses ubiquilin 2 as a cancer marker for urothelial cancer (renal pelvis cancer, ureteral cancer, and bladder cancer). Detection of ubiquilin 2 in a urine sample allows easy and accurate diagnosis of a possibility of urothelial cancer. The present invention is also applicable to the diagnosis of squamous cancer (esophageal cancer, cervical cancer, etc.).Type: GrantFiled: September 26, 2013Date of Patent: January 2, 2018Assignee: PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITYInventors: Noboru Konishi, Keiji Shimada
-
Publication number: 20170315142Abstract: Disclosed is a method for analyzing a blood specimen, including the steps of: coagulating a blood specimen in the presence of an activating agent for fibrinolytic system to acquire a coagulation waveform; and acquiring information about fibrinolytic capacity of the blood specimen based on the acquired coagulation waveform.Type: ApplicationFiled: April 27, 2017Publication date: November 2, 2017Applicants: SYSMEX CORPORATION, PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITYInventors: Midori SHIMA, Keiji NOGAMI, Tomoko MATSUMOTO, Sho SHINOHARA, Nobuo ARAI